LB1148
Sponsors
Leading BioSciences, Inc, Palisade Bio, Newsoara Biopharma Co., Ltd.
Conditions
COVID-19COVID-19 PneumoniaCoronavirus Disease 2019Covid19Gastro-Intestinal DisorderIleusPost-Operative AdhesionsSeptic Shock
Phase 2
Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148
TerminatedNCT02317549
Start: 2015-04-30End: 2016-03-31Updated: 2020-06-01
A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection
CompletedNCT02836470
Start: 2019-10-01End: 2023-09-08Updated: 2024-06-21
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
WithdrawnNCT04390217
Start: 2021-10-31End: 2022-03-31Updated: 2022-05-13
Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus
CompletedNCT05056935
Start: 2019-07-09End: 2020-08-08Updated: 2021-09-27